Elsevier

Biochemical Pharmacology

Volume 36, Issue 20, 15 October 1987, Pages 3365-3369
Biochemical Pharmacology

The disposition of primaquine in the isolated perfused rat liver: Stereoselective formation of the carboxylic acid metabolite

https://doi.org/10.1016/0006-2952(87)90312-1Get rights and content

Abstract

The disposition of (+) and (−) primaquine (PQ) was studied in the isolated perfused rat liver (IPRL) preparation following a bolus dose (2.0 mg diphosphate salt; N = 6) of each enantiomer. Perfusate plasma concentrations of PQ and the carboxylic acid metabolite (PQm) were determined using previously reported methods. To enable the simultaneous measurement of PQ and PQm in bile a selective and reproducible HPLC assay was developed. Clearance of (−)PQ (8.8 ± 2.9 ml min−1) was significantly greater than that of (+)PQ (5.5 ± 1.5 ml min−1) and the apparent volumes of distribution of (−)PQ (606 ± 182 ml) and (+)PQ (930 ± 171 ml) were significantly different. Stereoselectivity in the hepatic elimination efficiency was manifest as a significant reduction in half-life ((−)PQ 54 ± 29 min; (+)PQ 123 ± 33 min) and smaller area under the curve to infinity ((−)PQ254 ± 96μg ml−1.min, (+)PQ 387 ± 108 μg ml−1.min) for (−)PQ when compared with (+)PQ. A significantly greater peak concentration of PQm was achieved following administration of (−)PQ (0.61 ± 0.26 μg ml−1. min) than (+)PQ (0.19 ± 0.09 μg ml−1). There was no difference between the sum of the areas under the curve to 4hr for (+) and (−)PQ and the corresponding carboxylic acid metabolite (322 ± 64 μg ml−1 and 317 ± 75 μg ml min−1 respectively). There was no difference in the biliary clearance of (+) and (−)PQ (0.08 ± 0.02 ml min−1 and 0.14 ± 0.10 ml min−1 respectively) or the corresponding carboxylic acid metabolites 0.24 ± 0.13 ml min−1 and 0.29 ± 0.09 ml min−1). These results strongly suggest stereoselective formation of the carboxylic acid metabolite of primaquine. The significant increase in the volume of distribution of (+)PQ suggests the enantiomer has either an increased affinity for binding sites within the liver and/or erythrocytes or a decreased affinity for circulating perfusate albumin.

References (21)

  • J.K. Baker et al.

    J. Chromatogr.

    (1982)
  • C.D. Hufford et al.

    J. Pharm. Sci.

    (1983)
  • S.A. Ward et al.

    Biochem. Pharmac.

    (1987)
  • B. Silber et al.

    J. Pharm. Sci.

    (1982)
  • L.J. Bruce-Chwatt

    Essential Malariology

    (1980)
  • G.W. Mihaly et al.

    Br. J. clin. Pharmac.

    (1984)
  • J. Greaves et al.

    Br. J. clin. Pharmac.

    (1980)
  • J.K. Baker et al.

    Pharm. Res.

    (1984)
  • S.A. Ward et al.

    Drug Metab. Dispos.

    (1985)
  • A. Strother et al.

    Bull. W.H.O.

    (1981)
There are more references available in the full text version of this article.

Cited by (13)

  • Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers

    2022, Drug Metabolism and Pharmacokinetics
    Citation Excerpt :

    The fact that RPQ is rapidly converted into its carboxylic acid metabolite (cPQ) appears to account for the lower exposure with RPQ compared to SPQ. These observations reflect greater conversion of RPQ to cPQ in liver [12,28]. At 24-h after the oral administration of RPQ or RSPQ, the concentrations of cPQ are still sustained, as much as 100 times above the level of parent drug PQ.

  • Antimalarial Drugs

    2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
View all citing articles on Scopus

This work received financial support from the UNDP/ WHO/World Bank Special Programme for Research and Training in Tropical Diseases.

View full text